Gabriel Brooks Sells 12,616 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Gabriel Brooks sold 12,616 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total value of $81,247.04. Following the transaction, the insider owned 84,092 shares in the company, valued at $541,552.48. This trade represents a 13.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Gabriel Brooks also recently made the following trade(s):

• On Monday, February 2nd, Gabriel Brooks sold 28,335 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $182,477.40.
• On Monday, February 2nd, Gabriel Brooks sold 28,335 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total transaction of $182,477.40.

Solid Biosciences Price Performance

Shares of SLDB stock opened at $6.52 on Friday. The firm has a market cap of $507.97 million, a P/E ratio of -2.62 and a beta of 2.67. Solid Biosciences Inc. has a 1-year low of $2.41 and a 1-year high of $7.37. The firm’s 50-day simple moving average is $5.84 and its 200-day simple moving average is $5.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SLDB. Quantum Private Wealth LLC increased its holdings in Solid Biosciences by 3.9% during the 3rd quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after purchasing an additional 3,500 shares during the last quarter. Legal & General Group Plc grew its position in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after buying an additional 4,534 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after acquiring an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after acquiring an additional 10,585 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SLDB. Barclays set a $9.00 price target on shares of Solid Biosciences and gave the company an “overweight” rating in a report on Tuesday, November 4th. Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a report on Wednesday, January 14th. Finally, Wall Street Zen lowered Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.70.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.